Literature DB >> 33718229

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer.

Dan Pu1, Liyuan Yin1, Lin Huang1, Changlong Qin1, Yuwen Zhou2, Qiang Wu1, Yan Li1, Qinghua Zhou1, Lu Li1.   

Abstract

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E2 (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.
Copyright © 2021 Pu, Yin, Huang, Qin, Zhou, Wu, Li, Zhou and Li.

Entities:  

Keywords:  cancer; celecoxib; combination therapy; cyclooxygenase-2; immunotherapy

Year:  2021        PMID： 33718229      PMCID： PMC7952860          DOI： 10.3389/fonc.2021.637504

Source DB:  PubMed          Journal:  Front Oncol        ISSN： 2234-943X            Impact factor:   6.244


  53 in total

Review 1.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  Immunotherapy: The path to win the war on cancer?

Authors:  Suzanne L Topalian; Jedd D Wolchok; Timothy A Chan; Ira Mellman; Karolina Palucka; Jacques Banchereau; Steven A Rosenberg; K Dane Wittrup
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 3.  Cyclooxygenase-2 in gastrointestinal malignancies.

Authors:  Ganji Purnachandra Nagaraju; Bassel F El-Rayes
Journal:  Cancer       Date:  2019-02-12       Impact factor: 6.860

4.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 5.  COX-2 and PGE2-dependent immunomodulation in breast cancer.

Authors:  Edward P Chen; Emer M Smyth
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-31       Impact factor: 3.072

6.  Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs.

Authors:  Chiara Porta; Francesca Maria Consonni; Sara Morlacchi; Sabina Sangaletti; Augusto Bleve; Maria Grazia Totaro; Paola Larghi; Monica Rimoldi; Claudio Tripodo; Laura Strauss; Stefania Banfi; Mariangela Storto; Tiziana Pressiani; Lorenza Rimassa; Silvia Tartari; Alessandro Ippolito; Andrea Doni; Giulia Soldà; Stefano Duga; Viviana Piccolo; Renato Ostuni; Gioacchino Natoli; Vincenzo Bronte; Fiorella Balzac; Emilia Turco; Emilio Hirsch; Mario P Colombo; Antonio Sica
Journal:  Cancer Res       Date:  2020-04-07       Impact factor: 12.701

Review 7.  PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review.

Authors:  Andrew T Kunzmann; Liam J Murray; Chris R Cardwell; Charlene M McShane; Una C McMenamin; Marie M Cantwell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-06-27       Impact factor: 4.254

8.  Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.

Authors:  Nune Markosyan; Edward P Chen; Rebecca A Evans; Victoire Ndong; Robert H Vonderheide; Emer M Smyth
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

9.  Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Authors:  Hirokazu Matsushita; Matthew D Vesely; Daniel C Koboldt; Charles G Rickert; Ravindra Uppaluri; Vincent J Magrini; Cora D Arthur; J Michael White; Yee-Shiuan Chen; Lauren K Shea; Jasreet Hundal; Michael C Wendl; Ryan Demeter; Todd Wylie; James P Allison; Mark J Smyth; Lloyd J Old; Elaine R Mardis; Robert D Schreiber
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

Review 10.  Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.

Authors:  Yukinori Take; Shinichi Koizumi; Atsushi Nagahisa
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561
View more
  12 in total

Review 1.  Myeloid cell-targeted therapies for solid tumours.

Authors:  Sangeeta Goswami; Swetha Anandhan; Deblina Raychaudhuri; Padmanee Sharma
Journal:  Nat Rev Immunol       Date:  2022-06-13       Impact factor: 53.106

Review 2.  Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation.

Authors:  K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2022-06-13       Impact factor: 4.617

Review 3.  Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers.

Authors:  Lindsey Carlsen; Kelsey E Huntington; Wafik S El-Deiry
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

4.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

Review 5.  Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.

Authors:  Somayeh Vafaei; Angelina O Zekiy; Ramadhan Ado Khanamir; Burhan Abdullah Zaman; Arman Ghayourvahdat; Hannaneh Azimizonuzi; Majid Zamani
Journal:  Cancer Cell Int       Date:  2022-01-03       Impact factor: 5.722

6.  Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.

Authors:  Francesca Lombardi; Francesca Rosaria Augello; Serena Artone; Mitilda Karoli Gugu; Maria Grazia Cifone; Benedetta Cinque; Paola Palumbo
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 7.  RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription.

Authors:  Choon Ping Tan; Laura Sinigaglia; Valentí Gomez; Joanna Nicholls; Nagy A Habib
Journal:  Molecules       Date:  2021-10-28       Impact factor: 4.411

Review 8.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

Review 9.  Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.

Authors:  Adel Naimi; Rebar N Mohammed; Ahmed Raji; Supat Chupradit; Alexei Valerievich Yumashev; Wanich Suksatan; Mohammed Nader Shalaby; Lakshmi Thangavelu; Siavash Kamrava; Navid Shomali; Armin D Sohrabi; Ali Adili; Ali Noroozi-Aghideh; Ehsan Razeghian
Journal:  Cell Commun Signal       Date:  2022-04-07       Impact factor: 5.712

Review 10.  The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition.

Authors:  Fernán Gómez-Valenzuela; Enrico Escobar; Ricardo Pérez-Tomás; Viviana P Montecinos
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.